Literature DB >> 15548548

Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.

Birgit Zucker1, Ruth Luthi-Carter, Jibrin A Kama, Anthone W Dunah, Edward A Stern, Jonathan H Fox, David G Standaert, Anne B Young, Sarah J Augood.   

Abstract

Transcriptional dysregulation has been described as a central mechanism in the pathogenesis of Huntington's disease (HD), in which medium spiny projection neurons (MSN) selectively degenerate whereas neuronal nitric-oxide-synthase-positive interneurons (nNOS-IN) survive. In order to begin to understand this differential vulnerability we compared mRNA levels of selected genes involved in N-methyl-D-aspartate (NMDA) glutamate receptor and calcium (Ca2+) signaling pathways in MSN and nNOS-IN from 12-week-old R6/2 mice, a transgenic mouse model of HD and wild-type littermates. We undertook a laser capture microdissection (LCM) study to examine the contribution of transcriptional dysregulation in candidate genes involved in these two signaling pathways in discrete populations of striatal neurons. The use of LCM in combination with quantitative real-time polymerase chain reaction (Q-PCR) allowed us to quantify the neuronal abundance of candidate mRNAs. We found different transcriptional alterations in R6/2 neurons for both MSN and nNOS-IN, indicating that global transcriptional dysregulation alone does not account for selective vulnerability. Further, we observed a striking enrichment of several mRNAs in the nNOS-IN population, including that for the NMDA receptor subunit NR2D, the postsynaptic density protein 95 (PSD-95) and the huntingtin-associated protein 1 (HAP1) as well as nitric-oxide-synthase (nNOS) mRNA itself. The higher expression levels of these molecules in nNOS-IN when compared with MSN together with an association of nNOS, NR2D and HAP1 in a protein complex with PSD-95 suggest that these proteins may be involved in protective pathways that contribute to the resistance of this interneuron population to neurodegeneration in HD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548548     DOI: 10.1093/hmg/ddi014

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

1.  Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Authors:  Birgit Zucker; Jibrin A Kama; Alexandre Kuhn; Doris Thu; Lianna R Orlando; Anthone W Dunah; Ozgun Gokce; David M Taylor; Johann Lambeck; Bernd Friedrich; Katrin S Lindenberg; Richard L M Faull; Cornelius Weiller; Anne B Young; Ruth Luthi-Carter
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

2.  Light responses and morphology of bNOS-immunoreactive neurons in the mouse retina.

Authors:  Ji-Jie Pang; Fan Gao; Samuel M Wu
Journal:  J Comp Neurol       Date:  2010-07-01       Impact factor: 3.215

3.  Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element.

Authors:  Serene Keilani; Samira Chandwani; Georgia Dolios; Alexey Bogush; Heike Beck; Antonis K Hatzopoulos; Gadiparthi N Rao; Elizabeth A Thomas; Rong Wang; Michelle E Ehrlich
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

4.  Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.

Authors:  Amy B Ryan; Scott O Zeitlin; Heidi Scrable
Journal:  Neurobiol Dis       Date:  2006-09-15       Impact factor: 5.996

5.  Time dependent changes of striatal interneurons after focal cerebral ischemia in rats.

Authors:  M Sakuma; N Hyakawa; H Kato; T Araki
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

6.  Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.

Authors:  Heike Runne; Alexandre Kuhn; Edward J Wild; Wirahpati Pratyaksha; Mark Kristiansen; Jeremy D Isaacs; Etienne Régulier; Mauro Delorenzi; Sarah J Tabrizi; Ruth Luthi-Carter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

7.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

Review 8.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

9.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

10.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.